Hormonal treatment in breast cancer;Hormonothérapie du cancer du sein

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 39, Issue 8 SUPPL., 2010, Pages

  Delozier, T ^a  

^a Centre Franois Baclesse   (France)

Author keywords

Aromatase inhibitors; Breast cancer; Hormonal treatment; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADVANCED CANCER; BONE DENSITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; ESTROGEN SYNTHESIS; HUMAN; POSTMENOPAUSE; REVIEW; TUMOR CELL;

EID: 78649637508     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgyn.2010.10.004     Document Type: Short Survey

References (59)

1. G.T. Beatson On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases Lancet 1896 104 107
2. W.F. Anderson, B.E. Chen, I. Jatoi, and P.S. Rosenberg Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer Breast Cancer Res Treat 100 2006 121 126
3. R. Hahnel, and E. Twaddle Estrogen receptors in human breast cancer. 1- Methodology and characterization of receptors Steroids 18 1971 653 680
4. S. Kobayashi Studies on the estrogen-receptors in human breast cancer Nagoya Med J 16 1971 165 176
5. M. Gorlich, and E. Heise Determination of estradiol receptors in human breast carcinoma Arch Geschwulstforsch 38 1971 139 149
6. W.L. McGuire Estrogen receptors in human breast cancer J Clin Invest 52 1973 73 77
7. D.P. Edwards, G.C. Chamness, and W.L. McGuire Estrogen and progesterone receptor proteins in breast cancer Biochim Biophys Acta 560 1979 457 486
8. E.V. Jensen, G.E. Block, S. Smith, K. Kyser, and E.R. Desombre Estrogen receptors and breast cancer response to adrenalectomy Natl Cancer Inst Monogr 34 1971 55 70
9. W.L. McGuire, G.C. Chamness, M.E. Costlow, and N.J. Richert Steroids and human breast cancer J Steroid Biochem 6 1975 723 727
10. M.O. Vilain, A. Delobelle-Deroide, and F. Bloget Immunohistochemical detection of estradiol and progesterone receptors in paraffin sections after treatment with microwaves. Comparison with biochemical assay of receptors in a series of 123 breast cancers with determination of the threshold of optimal positivity Ann Pathol 17 1997 82 88
11. R.M. Elledge, S. Green, and R. Pugh Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study Int J Cancer 89 2000 111 117
12. B. Zafrani, M.H. Aubriot, and E. Mouret High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases Histopathology 37 2000 536 545
13. M.P. Leers, B. Schutte, P.H. Theunissen, F.C. Ramaekers, and M. Nap A novel flow cytometric steroid hormone receptor assay for paraffin-embedded breast carcinomas: an objective quantification of the steroid hormone receptors and direct correlation to ploidy status and proliferative capacity in a single-tube assay Hum Pathol 31 2000 584 592
14. A. Rhodes, B. Jasani, A.J. Balaton, D.M. Barnes, and K.D. Miller Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening J Clin Pathol 53 2000 688 696
15. D.C. Allred, J.M. Harvey, M. Berardo, and G.M. Clark Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 1998 155 168
16. L.C. Collins, M.L. Botero, and S.J. Schnitt Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases Am J Clin Pathol 123 2005 16 20
17. J. Andersen, and H.S. Poulsen Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer Cancer 64 1989 1901 1908
18. W.R. Bezwoda, J.D. Esser, R. Dansey, I. Kessel, and M. Lange The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen Cancer 68 1991 867 872
19. P. Bonomi, M. Gale, and J. Von Roenn Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen Semin Oncol 15 1988 26 33
20. P.Z. Chen, Z. Mei, X.Y. Yao, and X.G. Meng Selection of hormone-responsive advanced breast cancer with a cytoplasmic estrogen receptor assay. Analysis of 100 cases Cancer 63 1989 139 142
21. A. Howell, R.N. Harland, and D.M. Barnes Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment Cancer Res 47 1987 300 304
22. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1998 1451 1467
23. M. De Laurentiis, G. Arpino, and E. Massarelli A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer Clin Cancer Res 11 2005 4741 4748
24. E.C. Dees, and N.E. Davidson Ovarian ablation as adjuvant therapy for breast cancer Semin Oncol 28 2001 322 331
25. R. Sainsbury Ovarian ablation as a treatment for breast cancer Surg Oncol 12 2003 241 250
26. C. Featherstone, A.N. Harnett, and A.M. Brunt Ultrasound localization of the ovaries for radiation-induced ovarian ablation Clin Oncol (R Coll Radiol) 11 1999 393 397
27. L.L. Hughes, R.J. Gray, and L.J. Solin Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study Cancer 101 2004 969 972
28. S.F. Leung, S.Y. Tsao, P.M. Teo, P.H. Choi, and W.C. Shiu Ovarian ablation failures by radiation: a comparison of two dose schedules Br J Radiol 64 1991 537 538
29. A.J. Sasco, G. Chaplain, E. Amoros, and S. Saez Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy Epidemiology 7 1996 9 13
30. H. Mignotte, C. Lasset, and V. Bonadona Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération nationale des centres de lutte contre le cancer (FNCLCC) Int J Cancer 76 1998 325 330
31. C.J. Featherstone, A.N. Harnett, A.M. Brunt, and L. Johnson Methods of ovarian suppression used in the UK Breast 11 2002 23 29
32. M. Kaufmann, H. Schmid, L. Kiesel, and K. Klinga Therapy with gonadotropin releasing hormone agonists (zoladex) in premenopausal females with metastastic breast cancer Geburtshilfe Frauenheilkd 48 1988 528 532
33. N. Bundred Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer Cancer Invest 23 2005 173 181
34. A. Howell, J. Pippen, and R.M. Elledge Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials Cancer 104 2005 236 239
35. L. Mauriac, J.E. Pippen, A.J. Quaresma, S.Z. Gertler, and C.K. Osborne Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials Eur J Cancer 39 2003 1228 1233
36. A. Howell, J.F. Robertson, and P. Abram Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J Clin Oncol 22 2004 1605 1613
37. A. Valachis, D. Mauri, N.P. Polyzos, D. Mavroudis, V. Georgoulias, and G. Casazza Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials Crit Rev Oncol Hematol 73 2010 220 227
38. Robertson J, Dixon JM, Sibbering DM, et al. Tumor biomarker changes following pre-surgical treatment with 500 mg fulvestrant plus anastrozole versus 500 mg fulvestrant alone and 1 mg anastrozole alone. In: Thirty-Second Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, Dec 10-13, 2009. Cancer Res 2009;69(24):Abstract nr 24.
39. S. Ohno, Y. Rai, and H. Iwata Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1) Ann Oncol 2010 10.1093/annonc/mdq249
40. Bergh J, Jönsson PE, Lidbrink E, et al. First results from FACT - an open-label, randomized phase III study investigating loading dose of fulvestrant combined with anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer. In: Thirty-Second Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, Dec 10-13, 2009. Cancer Res 2009;69 (24):Abstract nr 23.
41. M.G. Jannuzzo, S.E. Di, R. Spinelli, N. Pirotta, P. Buchan, and A. Bello Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone Breast Cancer Res Treat 113 2009 491 499
42. M. Crump, C.A. Sawka, and G. DeBoer An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer Breast Cancer Res Treat 44 1997 201 210
43. J.G. Klijn, R.W. Blamey, F. Boccardo, T. Tominaga, L. Duchateau, and R. Sylvester Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials J Clin Oncol 19 2001 343 353
44. F. Boccardo, A. Rubagotti, and A. Perrotta Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study Ann Oncol 5 1994 337 342
45. H. Mouridsen, M. Gershanovich, and Y. Sun Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 2003 2101 2109
46. C. Gennatas, V. Michalaki, and E. Carvounis Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO) Tumori 92 2006 13 17
47. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation for early breast cancer. Cochrane Database Syst Rev 2000; CD000485.
48. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer J Natl Cancer Inst 88 1996 1834 1839
49. Swedish Breast Cancer Cooperative Group Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer J Natl Cancer Inst 88 1996 1543 1549
50. T. Delozier, M. Spielmann, and J. Mace-Lesec'h Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédé ration nationale des centres de lutte contre le cancer Breast Group J Clin Oncol 18 2000 3507 3512
51. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2.
52. A.S. Coates, A. Keshaviah, and B. Thurlimann Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 5 2007 486 492
53. R.C. Coombes, E. Hall, and L.J. Gibson A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081 1092 (Pubitemid 38298988)
54. R.C. Coombes, L.S. Kilburn, and C.F. Snowdon Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 2007 559 570
55. M. Baum, A. Buzdar, and J. Cuzick Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 2003 1802 1810
56. L. Mauriac, A. Keshaviah, and M. Debled Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial Ann Oncol 18 2007 859 867
57. Rea D, Hasenburg A, Seynaeve C, et al. Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer. In: Thirty-Second Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, Dec 10-13, 2009. Cancer Res 2009;69(24):Abstract nr 11.
58. H. Mouridsen, A. Giobbie-Hurder, and A. Goldhirsch Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 2009 766 776
59. V.O. Dezentje, N.J. van Blijderveen, and H. Gelderblom Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer J Clin Oncol 28 2010 2423 2429